TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23948058

Group type: EXPERIMENTAL
Intervention: Fab antivenom
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: F(ab')2 antivenom
Number of subjects: 12
Study: 20839665

Group type: EXPERIMENTAL
Intervention: Wavefront-guided LASIK
Number of subjects: 41

Group type: COMPARATOR
Intervention: Wavefront-optimized LASIK
Number of subjects: 41
Study: 18302514

Group type: EXPERIMENTAL
Intervention: Selenium (200 microg sodium selenite per day orally for 3 months)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: COMPARATOR
Intervention: Selenium vs. Placebo
Number of subjects: 36
Study: 16680261

Group type: EXPERIMENTAL
Intervention: Lifestyle enhancement program including health education, low caloric diet, and exercise for 26 weeks
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Lifestyle enhancement program
Number of subjects: 55
Study: 14571609

Group type: EXPERIMENTAL
Intervention: Shenfu injection (SFI) 1.0 ml/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Shenfu injection (SFI)
Number of subjects: 40
Study: 11230471

Group type: EXPERIMENTAL
Intervention: High-dose L-asparaginase (HD ASP) arm; weekly intramuscular administration of HD ASP 25,000 IU/m² for a total of 20 weeks.
Number of subjects: 705

Group type: COMPARATOR
Intervention: Standard treatment (SD ASP arm).
Number of subjects: 705
Study: 9692708

Group type: EXPERIMENTAL
Intervention: K‐Mag (70 mmol/day K, 35 mmol/day citrate and 17.6 mmol/day Mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Urocit‐K (70 mmol/day K and 23.4 mmol/day citrate)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 7908130

Group type: EXPERIMENTAL
Intervention: 50 mg dipyridamole with 1360 mg glutamic acid HCl (achlorhydric subjects)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 50 mg dipyridamole without pretreatment (achlorhydric subjects)
Number of subjects: 11

Group type: COMPARATOR
Intervention: 40 mg famotidine (control subjects)
Number of subjects: 11

Group type: COMPARATOR
Intervention: 50 mg dipyridamole with 40 mg famotidine (control subjects)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 50 mg dipyridamole (both groups)
Number of subjects: 11
Study: 2844492

Group type: EXPERIMENTAL
Intervention: Active marijuana (1.8% delta 9‐THC)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Task performance (serial acquisition task)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combination of drug and task performance
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30273288

Group type: EXPERIMENTAL
Intervention: Resistance Training (TG)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Nonexercise Control (CG)
Number of subjects: 33
Study: 30672252

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with hydro-acupuncture (1 mL Danshen injection per point, 7 days per injection for 2 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Regular acupuncture (once a day, six treatments per week for 2 weeks)
Number of subjects: 100
Study: 27427553

Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy (TRT) with T gel for 12 weeks, followed by cessation for 8 weeks
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Supervised exercise program for 20 weeks in addition to TRT
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (TRT alone)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Supervised exercise program for 20 weeks
Number of subjects: 50
Study: 26632125

Group type: EXPERIMENTAL
Intervention: lidocaine‐bupivacaine plus 1 ug/kg DEX retrobulbar block
Number of subjects: 200

Group type: COMPARATOR
Intervention: lidocaine‐bupivacaine retrobulbar block
Number of subjects: 200
Study: 23137954

Group type: EXPERIMENTAL
Intervention: Clinic management and home visits
Number of subjects: 544

Group type: COMPARATOR
Intervention: Clinic management only
Number of subjects: 544
Study: 21570549

Group type: EXPERIMENTAL
Intervention: Immediate insertion of Copper T380A IUD
Number of subjects: 215

Group type: COMPARATOR
Intervention: Delayed insertion of Copper T380A IUD
Number of subjects: 215
Study: 18638709

Group type: EXPERIMENTAL
Intervention: QuYuHuaTanTongLuo Decoction (QYHTTLD)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 69
Study: 17051484

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 10

Group type: COMPARATOR
Intervention: TNF-alpha antagonists
Number of subjects: 10
Study: 15339579

Group type: EXPERIMENTAL
Intervention: Qinggan Huoxue Recipe
Number of subjects: 0

Group type: COMPARATOR
Intervention: Xiao Chaihu Decoction
Number of subjects: 0

Group type: COMPARATOR
Intervention: General supportive treatment
Number of subjects: 0
Study: 10966000

Group type: EXPERIMENTAL
Intervention: Four-day infusion of fluorouracil (1000 mg/m2/day) plus vinorelbine (20 mg/m2/i.v. day 1 and 5), recycled every 3 weeks for a total of six courses.
Number of subjects: 48
Study: 9297886

Group type: EXPERIMENTAL
Intervention: Open appendectomy (group I)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (group II)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Both groups (open and laparoscopic)
Number of subjects: 32
Study: 29374658

Group type: EXPERIMENTAL
Intervention: 5-year HPV screening with partial genotyping and referral of HPV16/18-positive women to colposcopy (intervention Arm B)
Number of subjects: 121000

Group type: COMPARATOR
Intervention: 2.5-year image-read, liquid-based cytology (LBC) screening with HPV triage of low-grade smears (active control Arm A)
Number of subjects: 121000

Group type: EXPERIMENTAL
Intervention: LBC or dual-stained (p16INK4a and Ki-67) cytology testing (dual-stained cytology)
Number of subjects: 121000
Study: 27648523

Group type: EXPERIMENTAL
Intervention: everolimus (EVR) + mycophenolic acid (MPA)
Number of subjects: 71

Group type: COMPARATOR
Intervention: tacrolimus (TAC) + MPA
Number of subjects: 71
Study: 25439417

Group type: EXPERIMENTAL
Intervention: 10 mg of intravenous (IV) melatonin
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 22423090

Group type: EXPERIMENTAL
Intervention: Local energy model of pooling based on estimated receptive fields
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral responses to global stimuli
Number of subjects: 0
Study: 19342389

Group type: EXPERIMENTAL
Intervention: Miniaturized closed circuit CPB with the maquet‐cardiopulmonary MECC System (study group, n=60)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard CPB (control group, n=60)
Number of subjects: 120
Study: 16884468

Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 1250
Study: 14722678

Group type: EXPERIMENTAL
Intervention: FDG-PET delayed imaging
Number of subjects: 36

Group type: COMPARATOR
Intervention: MRI/CT
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: FDG-PET delayed imaging (retrospective evaluation with standardized uptake ratio)
Number of subjects: 36
Study: 11851748

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Serial casting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) for hemiplegia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Serial casting for hemiplegia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) for diplegia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Serial casting for diplegia
Number of subjects: 0
Study: 9457389

Group type: EXPERIMENTAL
Intervention: rIL-2 plus IFN-alpha plus cisplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dacarbazine plus cisplatin plus IFN-alpha plus rIL-2
Number of subjects: 0

Group type: COMPARATOR
Intervention: rIL-2 and/or IFN-alpha
Number of subjects: 0
Study: 7619241

Group type: EXPERIMENTAL
Intervention: Counselor group (N = 59)
Number of subjects: 102
Study: 3163527

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gel (1% applied interdentally 4 times/year)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Placebo gel (applied interdentally 4 times/year)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 220
Study: 31150753

Group type: EXPERIMENTAL
Intervention: Psychosocial family treatments during the first 9 months of the study
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Baseline medication exposure
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: More severe baseline depressive symptoms, suicidality, lower quality of life scores, and minority race/ethnicity
Number of subjects: 144
Study: 29526844

Group type: EXPERIMENTAL
Intervention: Endurance training (ET) - 8 weeks of running on treadmill at 60‐75% of VO2peak, 3 sessions per week
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Endurance training (ET)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (CONT) - no exercise training
Number of subjects: 20
Study: 28266150

Group type: EXPERIMENTAL
Intervention: Microcatheter-assisted trabeculotomy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Rigid probe trabeculotomy
Number of subjects: 62
Study: 25230094

Group type: EXPERIMENTAL
Intervention: Combination therapy (afamelanotide + NB‐UV‐B)
Number of subjects: 55

Group type: COMPARATOR
Intervention: NB‐UV‐B monotherapy
Number of subjects: 55
Study: 24444682

Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Parenteral Nutrition (PN)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Both EN and PN
Number of subjects: 178
Study: 21075452

Group type: EXPERIMENTAL
Intervention: Bright light treatment (BLT) for 6 weeks (10,000 lux, 30 min daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 24
Study: 18176328

Group type: EXPERIMENTAL
Intervention: Tipranavir boosted with ritonavir (TPV/r)
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Tipranavir boosted with ritonavir (TPV/r) added to dual-boosted regimens (LPV, SQV, APV)
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Dual PI regimen with TPV
Number of subjects: 315
Study: 17079856

Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glucocorticoids
Number of subjects: 0
Study: 15330032

Group type: EXPERIMENTAL
Intervention: HA-coated pins
Number of subjects: 23

Group type: COMPARATOR
Intervention: Uncoated pins
Number of subjects: 23
Study: 11783075

Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy
Number of subjects: 56

Group type: COMPARATOR
Intervention: Intravenous chemotherapy
Number of subjects: 56
Study: 9018028

Group type: EXPERIMENTAL
Intervention: Sustained-release carbidopa/levodopa (Sinemet CR 50/200)
Number of subjects: 618

Group type: COMPARATOR
Intervention: Immediate-release carbidopa/levodopa (Sinemet 25/100)
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Both treatment regimens
Number of subjects: 618
Study: 8343245

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 40
Study: 3829588

Group type: EXPERIMENTAL
Intervention: Maltotriose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glucose oligomer mixture
Number of subjects: 0

Group type: COMPARATOR
Intervention: 70 mmol/l sucrose
Number of subjects: 0

Group type: COMPARATOR
Intervention: 140 mmol/l glucose
Number of subjects: 0
Study: 31762043

Group type: EXPERIMENTAL
Intervention: Comprehensive school-based physical activity program (CSPAP)
Number of subjects: 3294
Study: 30958052

Group type: EXPERIMENTAL
Intervention: 11+ Kids intervention
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (usual warm-up)
Number of subjects: 31
Study: 28108537

Group type: EXPERIMENTAL
Intervention: hs-cTnT levels of 9-13 ng/L
Number of subjects: 8153

Group type: EXPERIMENTAL
Intervention: hs-cTnT levels of ≥14 ng/L
Number of subjects: 8153

Group type: EXPERIMENTAL
Intervention: hs-cTnT levels >8 ng/L
Number of subjects: 8153

Group type: EXPERIMENTAL
Intervention: hs-cTnT added to fully adjusted models including glucose
Number of subjects: 8153

Group type: COMPARATOR
Intervention: hs-cTnT levels ≤5 ng/L
Number of subjects: 8153
Study: 26291092

Group type: EXPERIMENTAL
Intervention: Active treatment for PAH
Number of subjects: 2762

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2762
Study: 23147520

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg twice daily for 4 weeks
Number of subjects: 599

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 599
Study: 21296237

Group type: EXPERIMENTAL
Intervention: Restricted elimination diet for 5 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Instructions for a healthy diet (control group)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Food challenge phase with high-IgG or low-IgG foods
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Food-specific IgG levels at baseline
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Challenge phase
Number of subjects: 100
Study: 19169168

Group type: EXPERIMENTAL
Intervention: 25 g of soy protein with 90 mg of isoflavones
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: 25 g of soy protein without isoflavones
Number of subjects: 203

Group type: COMPARATOR
Intervention: 25 g of milk protein (casein and whey)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Physical performance measurements
Number of subjects: 203
Study: 17061459

Group type: EXPERIMENTAL
Intervention: Omron M6 monitor (arm cuff, A/A, BHS validation)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Microlife BP-3AC1 monitor with MAM technology
Number of subjects: 152

Group type: COMPARATOR
Intervention: Comparison of both monitors
Number of subjects: 152
Study: 15598483

Group type: EXPERIMENTAL
Intervention: 31 gauge x 6 mm needle
Number of subjects: 62

Group type: COMPARATOR
Intervention: 29 gauge x 12.7 mm needle
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Shorter needle preference
Number of subjects: 62
Study: 11431132

Group type: EXPERIMENTAL
Intervention: Increasing caloric intake to offset high energy demand
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment with exogenous estrogen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment aimed at correcting metabolic abnormalities
Number of subjects: 0
Study: 9208356

Group type: EXPERIMENTAL
Intervention: Simvastatin (10 mg daily for 3 months)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 8215279

Group type: EXPERIMENTAL
Intervention: Monthly infusions of immune globulin at a dose of 500 mg/kg of body weight
Number of subjects: 49

Group type: COMPARATOR
Intervention: No immune globulin (control group)
Number of subjects: 49
Study: 2824045

Group type: EXPERIMENTAL
Intervention: Carboplatin (CBDCA) 400 mg/m2 iv every 4 weeks until relapse
Number of subjects: 141

Group type: COMPARATOR
Intervention: Iproplatin (CHIP) 270 mg/m2 iv every 4 weeks until relapse
Number of subjects: 141
Study: 30629813

Group type: EXPERIMENTAL
Intervention: csDMARD
Number of subjects: 205

Group type: COMPARATOR
Intervention: TNFi
Number of subjects: 205
Study: 31547861

Group type: EXPERIMENTAL
Intervention: Phototherapy and 20% albumin
Number of subjects: 118

Group type: COMPARATOR
Intervention: Phototherapy and saline
Number of subjects: 118
Study: 28419398

Group type: EXPERIMENTAL
Intervention: Ranibizumab (Lucentis; Genentech) - first intravitreal injection
Number of subjects: 84
Study: 25178900

Group type: EXPERIMENTAL
Intervention: Maternal baseline systolic blood pressure (SBP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal SBP change during pregnancy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Child's weight, baseline SBP, age, and sex
Number of subjects: 0
Study: 23827398

Group type: EXPERIMENTAL
Intervention: primary angioplasty ± abciximab
Number of subjects: 1301

Group type: EXPERIMENTAL
Intervention: MBG 0/1
Number of subjects: 1301

Group type: COMPARATOR
Intervention: MBG
Number of subjects: 1301
Study: 21067812

Group type: EXPERIMENTAL
Intervention: Infant Behavioral Assessment and Intervention Program (IBAIP) - 6-8 home visits during the first 8 months after birth
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 78
Study: 19404172

Group type: EXPERIMENTAL
Intervention: Epidural steroid injections
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Inpatient physical therapy program for 2 weeks
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 29
Study: 17498003

Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 954
Study: 15451124

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (TN) with intensive treatment
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (TN)
Number of subjects: 619
Study: 12053057

Group type: EXPERIMENTAL
Intervention: Nadolol (80 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Betaxolol (20 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9686464

Group type: EXPERIMENTAL
Intervention: Swimsuit
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sweater
Number of subjects: 72
Study: 8021483

Group type: EXPERIMENTAL
Intervention: Exercise three times a week at 70% maximum work capacity for 30 min
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dietary modification to achieve weight loss involving 4200 kj/day dietary restriction
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of exercise and dietary modification weight-loss programmes
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control period (no intervention)
Number of subjects: 30
Study: 2478793

Group type: EXPERIMENTAL
Intervention: Pimobendan (5 mg b.i.d.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Captopril (25 mg t.i.d.)
Number of subjects: 20
Study: 973004

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of prostaglandin F2alpha
Number of subjects: 40
Study: 30782213

Group type: EXPERIMENTAL
Intervention: Levothyroxine replacement therapy plus standard chronic heart failure treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard chronic heart failure therapy
Number of subjects: 0
Study: 28494046

Group type: EXPERIMENTAL
Intervention: Implant bed preparation before molar extractions
Number of subjects: 22

Group type: COMPARATOR
Intervention: Implant bed preparation after molar extractions
Number of subjects: 22
Study: 23981858

Group type: EXPERIMENTAL
Intervention: Individual cognitive therapy (ICT)
Number of subjects: 29
Study: 22345690

Group type: EXPERIMENTAL
Intervention: Sesame oil
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control oil
Number of subjects: 30
Study: 21449921

Group type: EXPERIMENTAL
Intervention: scGOS/lcFOS/pAOS
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 113
Study: 19386081

Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 134
Study: 16236380

Group type: EXPERIMENTAL
Intervention: Fast-food Mediterranean type diet rich in PAF antagonist
Number of subjects: 45

Group type: COMPARATOR
Intervention: Regular diet
Number of subjects: 45
Study: 15329300

Group type: EXPERIMENTAL
Intervention: Semantic category‐sorting task (Experiment 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Category‐based inductive reasoning task (Experiment 2)
Number of subjects: 0
Study: 11102252

Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 920

Group type: COMPARATOR
Intervention: Conservative strategy
Number of subjects: 920
Study: 9294390

Group type: EXPERIMENTAL
Intervention: Intervention group (221 women) received a letter asking them to seek a Pap test and a reminder letter 4 weeks later.
Number of subjects: 441

Group type: COMPARATOR
Intervention: Control group (220 women) received no letters.
Number of subjects: 441
Study: 8328996

Group type: EXPERIMENTAL
Intervention: Isradipine (5 mg)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 3886498

Group type: EXPERIMENTAL
Intervention: Aspirin (2 X 325 mg every 4 h to total 8 tablets during the first 24 h)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Acetaminophen (2 X 325 mg every 4 h to total 8 tablets during the first 24 h)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (identically packaged, 2 X 325 mg every 4 h to total 8 tablets during the first 24 h)
Number of subjects: 90
Study: 29797212

Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin aspart (0.15 unit/kg every two hours)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous regular insulin (0.05-0.1 unit/kg/hour)
Number of subjects: 50
Study: 27823994

Group type: EXPERIMENTAL
Intervention: Axillary vein technique
Number of subjects: 247

Group type: COMPARATOR
Intervention: Subclavian vein technique
Number of subjects: 247
Study: 24286360

Group type: EXPERIMENTAL
Intervention: Controlled release melatonin 2 mg (CRM)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 21862955

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 1009

Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 1009

Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 1009

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 1009
Study: 15863532

Group type: EXPERIMENTAL
Intervention: Subcutaneous suture closure alone
Number of subjects: 280

Group type: COMPARATOR
Intervention: Suture plus drain
Number of subjects: 280
Study: 12195841

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation powder via Easyhaler (400 micrograms/day)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Budesonide inhalation powder via Turbuhaler (400 micrograms/day)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Easyhaler
Number of subjects: 326

Group type: COMPARATOR
Intervention: Turbuhaler
Number of subjects: 326
Study: 9818662

Group type: EXPERIMENTAL
Intervention: Low calorie diet, appetite suppressant, nonsteroidal antiinflammatory drugs, and walking program for 6 weeks
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Walking program
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Change in percent body fat
Number of subjects: 22
Study: 8580388

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 532

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 532